Jazz Pharmaceuticals plc (JAZZ) announced long-term follow-up results, including the first-ever overall survival or OS findings, from the Phase 2b HERIZON-BTC-01 clinical trial of zanidatamab in previously treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer or BTC.
The company noted that Zanidatamab demonstrated a median overall survival (OS) of 15.5 months in patients with centrally confirmed immunohistochemistry (IHC) 2+ or 3+ and a median OS of 18.1 months in patients with IHC 3+ tumors.
The median duration of response (DoR), one of the trial's key secondary endpoints, increased by approximately 2 months to 14.9 months, compared to the previously reported findings. In the data cut, zanidatamab demonstrated a median estimated OS, another secondary endpoint, of 15.5 months in all patients with HER2+ BTC, 18.1 months in patients with IHC 3+ tumors, and 5.2 months in patients with IHC 2+ tumors. Results highlight the clinically meaningful benefits of sustained and durable responses with continued treatment with zanidatamab.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.